Top

BMC Oral Health

Published in:

Open Access 01-12-2023 | Research

Antitumor effect of toosendanin on oral squamous cell carcinoma via suppression of p-STAT3

Authors: Ye Wu, Lingling Chen, Cheng Feng, Tao Wang, Shaohai He, Dali Zheng, Lisong Lin

Published in: BMC Oral Health | Issue 1/2023

Abstract

Background

Toosendanin (TSN) exhibits potent antitumor activity against various tumor cell lines. However, its efficacy against oral squamous cell carcinoma (OSCC) remains unknown. Here, we investigated the effects of TSN on OSCC cells in vitro and verified them in vivo using a patient-derived xenograft (PDX) model.

Methods

The effect of TSN on OSCC cells was investigated by cytotoxicity assays and flow cytometry. The expression of proteins was detected by western blotting. An OSCC PDX model was constructed to further investigate the role of TSN in regulating the function of OSCC.

Results

The cell viability of CAL27 and HN6 cells decreased as the concentration of TSN increased within the experimental range. Compared with controls, TSN at lower doses inhibited cell proliferation and induced apoptosis through S-phase cell cycle arrest. TSN inhibited OSCC cell proliferation by downregulating the STAT3 pathway through the inhibition of STAT3 phosphorylation. After successful construction of the OSCC PDX model with high pathological homology to the primary tumor and treatment with an intraperitoneal injection of TSN, we showed that TSN significantly reduced the tumor size of the PDX model mice without obvious toxicity.

Conclusions

Both in vitro and in vivo, TSN significantly inhibits the proliferation and promoted apoptosis of OSCC cells. Furthermore, TSN demonstrates potent inhibition of STAT3 phosphorylation, indicating its potential as a promising therapeutic agent for OSCC. Therefore, TSN holds great promise as a viable drug candidate for the treatment of OSCC.

Available only for authorised users

Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell carcinoma—an update. CA: a cancer journal for clinicians. 2015;65(5):401–421. https://doi.org/10.3322/caac.21293.

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763.CrossRefPubMed

Ribeiro IP, Caramelo F, Esteves L, et al. Genomic and epigenetic signatures associated with survival rate in oral squamous cell carcinoma patients. J Cancer. 2018;9(11):1885–95. https://doi.org/10.7150/jca.23239.doi:10.7150/jca.23239.CrossRefPubMedPubMedCentral

Behranvand N, Nasri F, Zolfaghari Emameh R, et al. Chemotherapy: a double-edged sword in cancer treatment. Cancer Immunol Immunother. 2022;71(3):507–26. https://doi.org/10.1007/s00262-021-03013-3.CrossRefPubMed

Ng CX, Affendi MM, Chong PP, Lee SH. The Potential of Plant-Derived Extracts and Compounds to Augment Anticancer Effects of Chemotherapeutic Drugs. Nutr Cancer. 2022;74(9):3058–3076. https://doi.org/10.1080/01635581.2022.2069274.

Juarez P. Plant-derived anticancer agents: a promising treatment for bone metastasis. Bonekey Rep. 2014;3:599. https://doi.org/10.1038/bonekey.2014.94.CrossRefPubMedPubMedCentral

Mazumder K, Aktar A, Roy P, et al. A Review on Mechanistic Insight of Plant Derived Anticancer Bioactive Phytocompounds and Their Structure Activity Relationship. Molecules. 2022;27(9):3036. https://doi.org/10.3390/molecules27093036.

Shi YL, Li MF. Biological effects of toosendanin, a triterpenoid extracted from Chinese traditional medicine. Prog Neurobiol. 2007;82(1):1–10. https://doi.org/10.1016/j.pneurobio.2007.02.002.CrossRefPubMed

Fang XF, Cui ZJ. The anti-botulism triterpenoid toosendanin elicits calcium increase and exocytosis in rat sensory neurons. Cell Mol Neurobiol. 2011;31(8):1151–62. https://doi.org/10.1007/s10571-011-9716-z.CrossRefPubMed

10.

Zhang S, Cao L, Wang ZR, Li Z, Ma J. Anti-cancer effect of toosendanin and its underlying mechanisms. J Asian Nat Prod Res. 2019;21(3):270–83. https://doi.org/10.1080/10286020.2018.1451516.CrossRefPubMed

11.

Zhang B, Wang Z-F, Tang M-Z, Shi Y-L. Growth inhibition and apoptosis-induced effect on human cancer cells of toosendanin, a triterpenoid derivative from Chinese traditional medicine. Invest New Drugs. 2005;23:547–53. https://doi.org/10.1007/s10637-005-0909-5.CrossRefPubMed

12.

Tang M-Z, Wang Z-F, Shi Y-L. Involvement of cytochrome c release and caspase activation in toosendanin-induced PC12 cell apoptosis. Toxicology. 2004;201(1–3):31–8. https://doi.org/10.1016/j.tox.2004.03.023.CrossRefPubMed

13.

Zhang B, Wang Z-F, Tang M-Z, Shi Y-L. Growth Inhibition and Apoptosis-Induced Effect on Human Cancer Cells of Toosendanin, a Triterpenoid Derivative from Chinese Traditional Medicine. Investigational New Drugs. 2005;23(6):547–553. https://doi.org/10.1007/s10637-005-0909-5.

14.

Zhang J, Yang F, Mei X, et al. Toosendanin and isotoosendanin suppress triple-negative breast cancer growth via inducing necrosis, apoptosis and autophagy. Chem Biol Interact. 2022;351:109739. https://doi.org/10.1016/j.cbi.2021.109739.

15.

Zheng MD, Wang ND, Li XL, et al. Toosendanin mediates cisplatin sensitization through targeting Annexin A4/ATP7A in non-small cell lung cancer cells. J Nat Med. 2018;72:724–33. https://doi.org/10.1007/s11418-018-1211-0.CrossRefPubMed

16.

Kai W, Yating S, Lin M, et al. Natural product toosendanin reverses the resistance of human breast cancer cells to adriamycin as a novel PI3K inhibitor. Biochem Pharmacol. 2018;152:153–64. https://doi.org/10.1016/j.bcp.2018.03.022.CrossRefPubMed

17.

Kanikarla Marie P, Sorokin AV, Bitner LA, et al. Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts. Front Oncol. 2022;12:994333. https://doi.org/10.3389/fonc.2022.994333.

18.

De Angelis ML, Francescangeli F, Nicolazzo C, et al. An Orthotopic Patient-Derived Xenograft (PDX) Model Allows the Analysis of Metastasis-Associated Features in Colorectal Cancer. Front Oncol. 2022;12:869485. https://doi.org/10.3389/fonc.2022.869485.CrossRefPubMedPubMedCentral

19.

Yu X, Chen Y, Lu J, et al. Patient-derived xenograft models for gastrointestinal tumors: A single-center retrospective study. Front Oncol. 2022;12:985154. https://doi.org/10.3389/fonc.2022.985154.CrossRefPubMedPubMedCentral

20.

Wang CJ, Tong PJ, Zhu MY. The combinational therapy of trastuzumab and cetuximab inhibits tumor growth in a patient-derived tumor xenograft model of gastric cancer. Clin Transl Oncol. 2016;18(5):507–14. https://doi.org/10.1007/s12094-015-1397-5.CrossRefPubMed

21.

Hooper JE, Cantor EL, Ehlen MS, et al. A Patient-Derived Xenograft Model of Parameningeal Embryonal Rhabdomyosarcoma for Preclinical Studies. Sarcoma. 2015;2015: 826124. https://doi.org/10.1155/2015/826124.CrossRefPubMedPubMedCentral

22.

Luo M, He Y, Xie B, et al. Establishment and characterization of an ovarian yolk sac tumor patient-derived xenograft model. Pediatr Surg Int. 2021;37(8):1031–40. https://doi.org/10.1007/s00383-021-04895-1.CrossRefPubMed

23.

Dobbin ZC, Katre AA, Steg AD, et al. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget. 2014;5(18):8750–64. https://doi.org/10.18632/oncotarget.2373.CrossRefPubMedPubMedCentral

24.

Zou J, Yang Y, Yang Y, Liu X. Polydatin suppresses proliferation and metastasis of non-small cell lung cancer cells by inhibiting NLRP3 inflammasome activation via NF-kappaB pathway. Biomed Pharmacother. 2018;108:130–6. https://doi.org/10.1016/j.biopha.2018.09.051.CrossRefPubMed

25.

Meng L, Zhao Y, Bu W, et al. Bone mesenchymal stem cells are recruited via CXCL8-CXCR2 and promote EMT through TGF-β signal pathways in oral squamous carcinoma. Cell Prolif. 2020;53(8):e12859. https://doi.org/10.1111/cpr.12859.CrossRefPubMedPubMedCentral

26.

Zhang C, Gao H, Liu Z, et al. Mechanisms involved in the anti-tumor effects of Toosendanin in glioma cells. Cancer Cell Int. 2021;21(1):492. https://doi.org/10.1186/s12935-021-02186-2.

27.

Shao S, Li S, Liu C, et al. Toosendanin induces apoptosis of MKN-45 human gastric cancer cells partly through miR-23a-3p-mediated downregulation of BCL2. Mol Med Rep. 2020;22(3):1793–802. https://doi.org/10.3892/mmr.2020.11263.CrossRefPubMedPubMedCentral

28.

Gao T, Xie A, Liu X, et al. Toosendanin induces the apoptosis of human Ewing’s sarcoma cells via the mitochondrial apoptotic pathway. Mol Med Rep. 2019;20(1):135–40. https://doi.org/10.3892/mmr.2019.10224.CrossRefPubMedPubMedCentral

29.

Zhou Q, Wu X, Wen C, et al. Toosendanin induces caspase-dependent apoptosis through the p38 MAPK pathway in human gastric cancer cells. Biochem Biophys Res Commun. 2018;505(1):261–6. https://doi.org/10.1016/j.bbrc.2018.09.093.CrossRefPubMed

30.

Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798–809. https://doi.org/10.1038/nrc2734.CrossRefPubMedPubMedCentral

31.

Bromberg J. Stat proteins and oncogenesis. J Clin Invest. 2002;109(9):1139–42. https://doi.org/10.1172/JCI15617.CrossRefPubMedPubMedCentral

32.

Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117(Pt 8):1281–3. https://doi.org/10.1242/jcs.00963.CrossRefPubMed

33.

Yakata Y, Nakayama T, Yoshizaki A, Kusaba T, Inoue K, Sekine I. Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. Int J Oncol. 2007;30(2):437–42. https://doi.org/10.3892/ijo.30.2.437.CrossRefPubMed

34.

Kusaba T, Nakayama T, Yamazumi K, et al. Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncology Reports. 2006/06/01 2006;15(6):1445–1451. https://doi.org/10.3892/or.15.6.1445.

35.

Zhang T, Li J, Yin F, et al. Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3. Oncogene. 2017;36(47):6627–39. https://doi.org/10.1038/onc.2017.270.CrossRefPubMedPubMedCentral

36.

Gkouveris I, Nikitakis N, Avgoustidis D, Karanikou M, Rassidakis G, Sklavounou A. ERK1/2, JNK and STAT3 activation and correlation with tumor differentiation in oral SCC. Histol Histopathol. 2017;32(10):1065–76. https://doi.org/10.14670/HH-11-868.CrossRefPubMed

37.

Chen Y, Shao Z, Jiang E, et al. CCL21/CCR7 interaction promotes EMT and enhances the stemness of OSCC via a JAK2/STAT3 signaling pathway. J Cell Physiol. 2020;235(9):5995–6009. https://doi.org/10.1002/jcp.29525.CrossRefPubMed

38.

Huang X, Fang J, Lai W, et al. IL-6/STAT3 Axis Activates Glut5 to Regulate Fructose Metabolism and Tumorigenesis. Int J Biol Sci. 2022/5/16/ 2022;18(9):3668–3675. https://doi.org/10.7150/ijbs.68990.

39.

Alam M, Mishra R. Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer. Life Sci. Sep 1 2021;280:119705. https://doi.org/10.1016/j.lfs.2021.119705.

40.

Wei LY, Lin HC, Tsai FC, et al. Effects of Interleukin-6 on STAT3-regulated signaling in oral cancer and as a prognosticator of patient survival. Oral Oncol. 2022;124:105665. https://doi.org/10.1016/j.oraloncology.2021.105665.CrossRefPubMed

41.

Jiang M, Li B. STAT3 and Its Targeting Inhibitors in Oral Squamous Cell Carcinoma. Cells. 2022;11(19):3131. https://doi.org/10.3390/cells11193131.

42.

Zheng D. Orthotopic tumours, a hot topic for xenograft models? EBioMedicine. 2019;41:11–2. https://doi.org/10.1016/j.ebiom.2019.02.052.CrossRefPubMedPubMedCentral

43.

Silveira FM, Schmidt TR, Neumann B, et al. Impact of photobiomodulation in a patient-derived xenograft model of oral squamous cell carcinoma. Oral Dis. 2023;29(2):547–56. https://doi.org/10.1111/odi.13967.CrossRefPubMed

44.

Matossian MD, Giardina AA, Wright MK, et al. Patient-derived xenografts as an innovative surrogate tumor model for the investigation of health disparities in triple negative breast cancer. Women’s Health Reports. 2020;1(1):383–92. https://doi.org/10.1089/whr.2020.0037.CrossRefPubMedPubMedCentral

45.

Shimada Y, Naito T, Hayashi T, et al. Establishment of a patient-derived xenograft mouse model of pleomorphic leiomyosarcoma. J Toxicol Pathol. 2021;34(1):89–93. https://doi.org/10.1293/tox.2020-0061.CrossRefPubMed

46.

Isakau HA, Trukhacheva TV, Zhebentyaev AI, Petrov PT. HPLC study of chlorin e6 and its molecular complex with polyvinylpyrrolidone. Biomed Chromatogr. 2007;21(3):318–25. https://doi.org/10.1002/bmc.762.CrossRefPubMed

Title: Antitumor effect of toosendanin on oral squamous cell carcinoma via suppression of p-STAT3
Authors: Ye Wu
Lingling Chen
Cheng Feng
Tao Wang
Shaohai He
Dali Zheng
Lisong Lin
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: BMC Oral Health / Issue 1/2023
Electronic ISSN: 1472-6831
DOI: https://doi.org/10.1186/s12903-023-03602-x

2024 ASCO Annual Meeting

Springer Medicine

Antitumor effect of toosendanin on oral squamous cell carcinoma via suppression of p-STAT3

Abstract

Background

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Dental professionals’ perception of their role in the practice of oral health promotion: a qualitative interview study

Revolutionising dental technologies: a qualitative study on dental technicians’ perceptions of Artificial intelligence integration

Impact of endodontic irrigants on surface roughness of various nickel-titanium rotary endodontic instruments

Dental management of a pediatric patient with progressive familial intrahepatic cholestasis having dental anomalies: a case report and brief review of the literature

Effectiveness of chlorhexidine gels and chips in Periodontitis Patients after Scaling and Root Planing: a systematic review and Meta-analysis

Deciphering the role of Saliva in COVID 19: A global cross-sectional study on the knowledge, awareness and perception among dentists